Suwantarat Olesen Badal, S. Lob, S. Bouchillon, M. Hackel, D. Hoban; IHMA, Inc., Schaumburg, IL. coli Infections from Seven Centres in Low Prevalence Countries A. Rogers Castanheira, L. Deshpande, R. E. Mendes, R. N. Jones; JMI Lab., N Liberty, IA.

91 MONDAY SCIENTIFIC SESSIONS Final Program C1-680 Cumulative Resistance to the Novel Lpxc Inhibitor Chir-090 in Pseudomonas aeruginosa: Interplay of Efflux and Non Efflux Mechanisms

A. K. Jones

1 , S. Barnes 2 , K. Suefuji 1 , L. Xie 1 , J. R. Walker 2 , C. R. Dean 1 ; 1 Novartis Inst. for Biomedical Res., Emeryville, CA, 2 Genomics Inst. of the Novartis Res. Fndn., San Diego, CA. C1-681 Ozenoxacin. Selection of Resistant Mutants of Gram-Posi- tive Cocci

Y. López, Biologist

1 , M. Tato 2 , R. Cantón 2 , J. Vila 1 ; 1 Hosp. Clinic, Barce- lona, Spain, 2 Ramón y Cajal Univ. Hosp., Madrid, Spain. C1-682 Ozenoxacin Impact of Mutations in the gyrA y parC Genes of Clinical Gram-Positive Cocci in the MIC

Y. López

1 , M. Tato 2 , R. Cantón 2 , J. Vila 1 ; 1 Hosp. Clinic, Barcelona, Spain, 2 Ramón y Cajal Univ. Hosp., Madrid, Spain. C1-683 Prevalence and Molecular Characterization of Plasmid-Me- diated Quinolone Resistance in Prospective Bacteremic Clinical Isolates of Enterobacter spp. from Spain

J. Rodriguez-Martinez

1 , P. Díaz de Alba 1 , C. Ruiz de Alegría 2 , C. Martín- Gandul 3 , O. Gasch 4 , M. Cano 2 , F. Tubau 4 , J. Lepe 3 , R. Lara 5 , F. Rodriguez 5 , J. Rodriguez-Baño 1 , L. Martinez-Martinez 2 , M. Jiménez-Mejías 3 , A. Pascual 1 ; 1 Univ. of Seville, Seville, Spain, 2 UH Marques de Valdecilla, Santander, Spain, 3 UH Virgen del Rocio, Seville, Spain, 4 UH Bellvitge, Barcelona, Spain, 5 UH Reina Sofia, Cordoba, Spain. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program. ------------------------------------------------------------------------ 087 C2 Poster Session Diverse Resistance Issues in Enterobacteriaceae Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: C2-684 Host Risk Factors and Efflux Pump Gene Expressions Among E.coli Strains Isolated From Community-Acquired Urinary Tract Infections

F. Can

1 , O. Kurt Azap 2 , I. Dolapci 3 , A. Yesilkaya 2 , H. Arslan 2 , O. Ergonul 1 ; 1 Koc Univ., Istanbul, Turkey, 2 Baskent Univ., Ankara, Turkey, 3 Ankara Univ., Ankara, Turkey. C2-685 Antimicrobial Resistance and Virulence Markers of E. coli Isolated from Nosocomial Bloodstream Infection: A Study of the SCOPE Brazil Project A. C. Rochstroh, A. M. Doi, R. M. Silva, A. R. Marra, A. C. C. Pignatari; UNIFESP, Sao Paulo, Brazil. C2-686 Molecular Study of Escherichia coli Isolates from Outbreak of Infections After Transrectal Ultrasound-Guided Prostate Biopsy

N. Suwantarat

1 , S. Rudin 2 , D. Dumford 1 , S. Marshall 2 , A. M. Hujer 2 , K. M. Hujer 2 , R. A. Bonomo 2 , C. J. Donskey 2 ; 1 Case Western Reserve Univ., Cleveland, OH, 2 Louis Stokes VA Med. Ctr., Cleveland, OH. C2-687 Temporal Trends in Antibiotic Resistance among E. coli ST131 Isolates, 1968-2012

B. Olesen

1,2 , F. Scheutz 2 , J. Frimodt-Møller 1 , B. Johnston 3 , D. S. Hansen 1 , K. A. Krogfelt 2 , J. R. Johnson 3 ; 1 Hillerød Hosp., Hillerød, Denmark, 2 Statens Serum Inst., Copenhagen, Denmark, 3 VA Med. Ctr., Minneapolis, MN. C2-688 Regional Differences in Susceptibility of E. coli in Community-Acquired Versus Hospital-Associated Intra-Abdom- inal Infections: SMART 20102011

R. Badal, S. Lob, S. Bouchillon, M. Hackel, D. Hoban; IHMA, Inc., Schaumburg, IL.

C2-689 Risk Factors for 3rd Generation Cephalosporin Resistant Community Onset

E. coli Infections from Seven Centres in Low Prevalence Countries

B. A. Rogers

1,2 , P. R. Ingram 2,3 , N. Runnegar 2,4 , J. T. Freeman 2,5 , M. C. Pitman 2,6 , E. Athan 2,7 , S. Havers 1 , D. L. Paterson 1,2 ; 1 Univ. of Queensland, UQCCR, Brisbane, Australia, 2 The COOEE Study Group, ASID Clinical Res. Network, Qld, Australia, 3 The Royal Perth Hosptial, Perth, Australia, 4 Princess Alexandra Hosp., Woolloongabba, Australia, 5 Auckland District Hlth. Board, Auckland, New Zealand, 6 The Royal Darwin Hosp., Tiwi, Australia, 7 Barwon Hlth., Geelong, Australia. C2-690 Molecular Epidemiology of Non-Nosocomial Klebsiella pneumoniae Bloodstream KpB Infections M. Cubero, I. Grau, R. Pallares, J. Ayats, M. Cisnal, J. Liñares, C. Ardanuy; Hosp. Univ. Bellvitge, L´Hospitalet de Llobregat Barcelona, Spain. C2-691 New OXY-Variants from Klebisiella oxytoca KOX Bloodcul- ture BC Clinical Isolates Collected in U.S.A. Hospitals M. Castanheira, L. M. Deshpande, R. E. Mendes, R. N. Jones; JMI Lab., N Liberty, IA. C2-692 OqxAB, a Quinolone and Olaquindox Efflux Pump, is Widely Distributed Among Multidrug-Resistant MDR Klebsiella pneumoniae of Human Origin in the Northeast U.S.A.

F. Perez